Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31600670 | 0.98 | CYP3A4 (0.32) | CYP3A4TSHRMAPK1UHRF1TERT | |
| SCHEMBL31600503 | 0.81 | PDE10A (0.32) | — | |
| SCHEMBL17286614 | 0.74 | ALDH1A1 (0.34) | TSHRALDH1A1TDP1 | |
| SCHEMBL8066684 | 0.72 | GABRP (0.38) | KDM4EALDH1A1 | |
| SCHEMBL20299388 | 0.69 | TERT (0.35) | CYP3A4TSHRMAPK1UHRF1TERT | |
| SCHEMBL20299531 | 0.69 | DYRK1A (0.44) | CYP3A4UHRF1 | |
| SCHEMBL30888293 | 0.69 | KDM4E (0.40) | CYP3A4TSHRMAPK1UHRF1TERT | |
| SCHEMBL29361683 | 0.67 | PIM1 (0.42) | CYP3A4TSHRMAPK1UHRF1TERT | |
| SCHEMBL23465715 | 0.65 | MAPK1 (0.38) | CYP3A4TSHRMAPK1UHRF1TERT | |
| SCHEMBL31600402 | 0.65 | ESR2 (0.37) | TSHRMAPK1KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |